Skip to main content

Safety analysis of apixaban versus warfarin in patients with advanced kidney disease

Journal of Thrombosis and Thrombolysis volume 46, pages 246–252 (2018)Cite this article

Abstract

Anticoagulation in patients with advanced kidney disease, defined as those with an eGFR < 25 mL/min, including patients with end-stage renal disease on hemodialysis, remains an area of controversy and debate. Due to safety concerns regarding the increased risk for bleeding in this population, these patients have been excluded from all large-scale, randomized controlled trials to date. Warfarin and apixaban are both FDA-approved for use in this population and although warfarin remains the anticoagulant of choice, apixaban use is steadily increasing. This review combines relevant literature to better understand the risk versus benefit of anticoagulation in patients with severe kidney disease as well as the safety of apixaban versus warfarin in this population. High rates of bleed were found among both anticoagulants in those with severe kidney disease, suggesting that the risk for bleed associated with anticoagulation may not outweigh the benefit of treatment. Apixaban was found to be superior in rates of major bleed in those with ESRD on HD and may be superior to warfarin in those with an eGFR < 25 mL/min. However, large-scale, randomized clinical trials are needed to validate these results. With the continued development of novel agents there may be superior alternatives to apixaban and warfarin in those with severe kidney disease in the future.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Bansal V, Herzog C, Sarnak M et al (2017) Oral anticoagulants to prevent stroke in nonvavular atrial fibrillation in patients with CKD stage 5D: an NFK-KDOQI controversies report. Am J Kidney Dis 70(6):859–868. https://doi.org/10.1053/j.ajkd.2017.08.003

    Article  PubMed  CAS  Google Scholar 

  2. Brancacccio D, Neri L, Bellocchio F, Barbieri C et al (2016) Atrial fibrillation in dialysis patients: time to abandon warfarin? Int J Artif Organs 39(3):99–105. https://doi.org/10.5301/ijao.5000487

    Article  CAS  Google Scholar 

  3. Chan N, Bhagirath V, Eikelboom J (2015) Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 11:343–351. https://doi.org/10.2147/VHRM.S63060

    PubMed  PubMed Central  CAS  Article  Google Scholar 

  4. Chan K, Guigliano R, Patel M, Abramson S et al (2016) Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 67(24):2888–2899. https://doi.org/10.1016/j.acc.2016.02.082

    Article  PubMed  CAS  Google Scholar 

  5. Chang M, Yu Z, Shenker A, Wang J, Pursley J et al (2015) Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 56(5):637–645. https://doi.org/10.1002/jcph.633

    Article  PubMed  CAS  Google Scholar 

  6. Conway S, Hwang A, Ponte C, Gums J (2017) Laboratory and clinical monitoring of direct oral anticoagulants: what clinicians need to know. Pharmacotherapy 37(2):236–248. https://doi.org/10.1002/phar.1884

    Article  PubMed  Google Scholar 

  7. Fanikos J, Burnett A, Mahan C, Dobesh P (2017) Renal function considerations for stroke prevention in atrial fibrillation. Am J Med 130(9):1015–1023. https://doi.org/10.1016/j.amjmed.2017.04.015

    Article  PubMed  Google Scholar 

  8. Granger C, Alexander J, McMurray J et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 365:981–992. https://doi.org/10.1056/NEJMoa1107039

    Article  PubMed  CAS  Google Scholar 

  9. Harel Z, Chertow G, Shah P, Harel S, Dorian P, Yan A, Saposnik G et al (2017) Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol 33:737–746

    Article  PubMed  Google Scholar 

  10. Harel Z, Sood M, Perl J (2015) Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 24:183–192. https://doi.org/10.1097/MNH.0000000000000098

    Article  PubMed  CAS  Google Scholar 

  11. Ikeda K, Tachibana H (2015) Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythmia 32:42–50

    Article  Google Scholar 

  12. King B, el-Azhary R, McEvoy M et al (2017) Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol 56:1065–1070

    Article  PubMed  CAS  Google Scholar 

  13. Kufel W, Zayac A, Lehmann D et al (2016) Clinical application and pharmacodynamic monitoring of apixaban in a patient with end-stage renal disease requiring chronic hemodialysis. Pharmacotherapy 36(11):66–71. https://doi.org/10.1002/phar.1836

    Article  CAS  Google Scholar 

  14. Mavrakanas T, Samer C, Nessim S et al (2017) Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 28:2241–2248. https://doi.org/10.1681/ASN.2016090980

    Article  PubMed  PubMed Central  Google Scholar 

  15. Pathak R, Pandit A, Karmacharya P et al (2015) Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 115(3):323–327. https://doi.org/10.1016/j.amjcard.2014.10.042

    Article  PubMed  Google Scholar 

  16. Pelliccia F, Rosanio S, Marazzi G et al (2016) Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: focus on apixaban. Int J Cardiol 225:77–81. https://doi.org/10.1016/jijcard.2016.09.129

    Article  PubMed  Google Scholar 

  17. Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H (2017) Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2:291–298. https://doi.org/10.1002/rth2.12083

    Article  Google Scholar 

  18. Sarratt S, Nesbit R, Moye R (2017) Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann Pharmacother 51(6):445–450. https://doi.org/10.1177/1060028017694654

    Article  PubMed  CAS  Google Scholar 

  19. Skelley J, Thomason A, Nolen J (2018) Betrixaban (Bevyxxa) A direct-acting oral anticoagulant factor Xa inhibitor. Pharm Ther 43(2):85–88

    Google Scholar 

  20. Stanton B, Barasch N, Tellor K (2017) Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacother Publ 37(4):412–419. https://doi.org/10.1002/phar.1905

    Article  CAS  Google Scholar 

  21. Steuber T, Shiltz D, Cairns A, Ding Q, Binger K, Courtney J (2017) A multicenter analysis of factors associated with apixaban-related bleeding in hospitalized patients with end-stage renal disease of hemodialysis. Ann Pharmacother 51(11):954–960. https://doi.org/10.1177/1060028017717282

    Article  PubMed  CAS  Google Scholar 

  22. Wang X, Tirucherai G, Marbury T et al (2016) Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 56(5):628–636. https://doi.org/10.1002/jcph.628

    Article  PubMed  CAS  Google Scholar 

  23. Wendte J, Voss G, VanOverschelde B (2016) Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. Am J Health-Syst Pharm 73:563–567. https://doi.org/10.2146/ajhp150360

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Internal Medicine-Pediatrics, Loma Linda University Medical Center, 11234 Anderson St, Loma Linda, CA, 92354, USA

    Michael Bowie

  2. Department of Pharmacy, Children’s Hospital of Orange County, 1201 West La Veta Ave, Orange, CA, 92868, USA

    Violet Valencia

  3. Department of Pathology and Laboratory Medicine, University of California, Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA

    Ingrid Perez-Alvarez & Minh-Ha Tran

Authors
  1. Michael Bowie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Violet Valencia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingrid Perez-Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Minh-Ha Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Bowie.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bowie, M., Valencia, V., Perez-Alvarez, I. et al. Safety analysis of apixaban versus warfarin in patients with advanced kidney disease. J Thromb Thrombolysis 46, 246–252 (2018). https://doi.org/10.1007/s11239-018-1683-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-018-1683-5

Keywords

  • Apixaban
  • Warfarin
  • Anticoagulation
  • Renal insufficiency
  • End-stage renal disease
  • Hemodialysis